Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)


The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD).

The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine.

The study will evaluate the effectiveness of Nantheiatm ATL5, an investigational drug using cannabidiol in ANANDA's proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA).

(Clinical Trials.gov Identifier NCT05269459)

"This is our second clinical trial targeting PTSD. We are excited that UNMC's research team has partnered with us to evaluate our promising drug for this very debilitating condition," said Sohail R. Zaidi, ANANDA's Chief Executive Officer. "It is an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options."

"Advancing evidence-based research into new therapeutics to provide a large PTSD patient population with new innovative treatment options is a key objective for our research team," Dr. Rizzo said. "We are delighted to be collaborating with ANANDA Scientific on this trial."

Dr. Rizzo also is the director of the National Institutes of Health's Great Plains IDeA Clinical and Translational Research Network. He chairs the executive committee of the American Brain Coalition which advocates to advance research for neurological cures.

Dr. Rizzo's research team will include Jennifer Merickel, Ph.D., Cognitive Neuroscientist and Assistant Professor in the UNMC Department of Neurological Sciences and Brigette Vaughan, an Advanced Practice Registered Nurse, Clinician and Researcher in the UNMC Department of Psychiatry.

This phase II double-blind, placebo controlled, randomized clinical study is planning to enroll 240 participants to provide rigorous clinical and real-world evaluation of the efficacy and safety of Nantheiatm ATL5.

ABOUT NANTHEIAtm ATL5

Nantheiatm ATL5 is an investigational drug that uses cannabidiol in ANANDA's propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA's Liquid Structuretm delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol. Nantheiatm ATL5 is an oral product with 100mg cannabidiol per softgel capsule.

ABOUT University of Nebraska Medical Center

As Nebraska's only public academic health sciences center, UNMC is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving the state and its communities through award-winning outreach. UNMC has six colleges and two institutes, serving more than 4,200 students in two dozen programs. Researchers at UNMC perform cutting-edge research in neurological sciences, oncology, infectious disease, and other key areas.

ABOUT ANANDA SCIENTIFIC

ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The company employs patented delivery technology to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its clinical portfolio. Consistent with its strong research-based data, the company has a growing pipeline of nutraceutical over-the-counter products. ANANDA has successfully launched these products in the U.S., Australia, and the U.K., with expansion into additional markets such as the EU, China, Africa, and other countries in Asia.


These press releases may also interest you

at 13:00
The "Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) - Global Forecast...

at 13:00
Founded in 2017, Belkins grew to become the leading provider of lead generation and appointment setting services in only 5 years. Now, after 900+ happy customers and over 200K booked appointments, Belkins is ranked #1 of the Top B2B Lead Generation...

at 13:00
Vertech is proud to announce that we have received the 2022 Integrator of the Year Award by CSIA. This award recognizes Vertech's commitment to advancing our industry by designing innovative industrial automation solutions that improve productivity...

at 12:51
Team Queso, a leading esports club in mobile...

at 12:49
Vast Therapeutics announces promising results with a nitric oxide releasing drug candidate under investigation for infections caused by Mycobacterium abscessus, a multi-drug resistant bacteria for which there are currently no FDA-approved treatments....

at 12:34
Empowering young people from diverse backgrounds across the globe is central to addressing global challenges like climate change. AFS Intercultural Programs, a global non-profit educational exchange organization, is proud to launch a new scholarship...



News published on 17 may 2022 at 07:10 and distributed by: